TWI850539B - 顆粒及使用其之製劑 - Google Patents

顆粒及使用其之製劑 Download PDF

Info

Publication number
TWI850539B
TWI850539B TW110108516A TW110108516A TWI850539B TW I850539 B TWI850539 B TW I850539B TW 110108516 A TW110108516 A TW 110108516A TW 110108516 A TW110108516 A TW 110108516A TW I850539 B TWI850539 B TW I850539B
Authority
TW
Taiwan
Prior art keywords
polymer
molten component
raw material
granules
molten
Prior art date
Application number
TW110108516A
Other languages
English (en)
Chinese (zh)
Other versions
TW202200118A (zh
Inventor
吉原尚輝
橋本翔太
木全崚太
Original Assignee
日商澤井製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商澤井製藥股份有限公司 filed Critical 日商澤井製藥股份有限公司
Publication of TW202200118A publication Critical patent/TW202200118A/zh
Application granted granted Critical
Publication of TWI850539B publication Critical patent/TWI850539B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)
TW110108516A 2020-03-11 2021-03-10 顆粒及使用其之製劑 TWI850539B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062988083P 2020-03-11 2020-03-11
US62/988,083 2020-03-11

Publications (2)

Publication Number Publication Date
TW202200118A TW202200118A (zh) 2022-01-01
TWI850539B true TWI850539B (zh) 2024-08-01

Family

ID=77670617

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110108516A TWI850539B (zh) 2020-03-11 2021-03-10 顆粒及使用其之製劑

Country Status (7)

Country Link
US (1) US20230014578A1 (https=)
EP (1) EP4119129A4 (https=)
JP (2) JP7487290B2 (https=)
KR (1) KR20220123689A (https=)
CN (1) CN115209876A (https=)
TW (1) TWI850539B (https=)
WO (1) WO2021182467A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7817300B2 (ja) * 2023-02-14 2026-02-18 沢井製薬株式会社 コーティング顆粒、コーティング顆粒を含む製剤及びそれらの製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2915653B2 (ja) * 1991-11-14 1999-07-05 第一製薬株式会社 マスクされた粒状物
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
JP4310605B2 (ja) * 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
KR100913281B1 (ko) * 2002-02-21 2009-08-21 오츠카 세이야쿠 가부시키가이샤 서방 제제 및 그의 제조 방법
JP4779970B2 (ja) * 2004-06-03 2011-09-28 大正製薬株式会社 経口製剤およびその製造方法
JP5905872B2 (ja) * 2010-04-07 2016-04-20 ルピン・リミテッド タペンタドールの制御放出医薬組成物
FR2999937B1 (fr) * 2012-12-21 2015-01-09 Sanofi Sa Unite solide a haute teneur en fexofenadine et son procede de preparation
JP2015054822A (ja) * 2013-09-10 2015-03-23 ニプロ株式会社 クロピドグレル含有錠剤およびその製造方法
WO2017196712A1 (en) * 2016-05-09 2017-11-16 Dispersol Technologies, Llc Improved drug formulations
JP2018083809A (ja) * 2016-11-16 2018-05-31 沢井製薬株式会社 シロドシン含有粒子の製造方法及びシロドシン含有口腔内崩壊錠の製造方法
JP6895779B2 (ja) * 2017-03-17 2021-06-30 東和薬品株式会社 アジルサルタン含有固形医薬組成物

Also Published As

Publication number Publication date
EP4119129A1 (en) 2023-01-18
WO2021182467A1 (ja) 2021-09-16
EP4119129A4 (en) 2024-01-24
KR20220123689A (ko) 2022-09-08
JP2024063111A (ja) 2024-05-10
CN115209876A (zh) 2022-10-18
JP7487290B2 (ja) 2024-05-20
JPWO2021182467A1 (https=) 2021-09-16
TW202200118A (zh) 2022-01-01
US20230014578A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
JP4980527B2 (ja) 酸に不安定な活性化合物を含有する新規の製剤および投与形
KR100424931B1 (ko) 서방성입상제제및그제조방법
JP2002154954A (ja) トラマドール又はその塩を含む鎮痛剤
JPWO1996019200A1 (ja) 徐放性粒状製剤およびその製造方法
KR100389606B1 (ko) 프란루카스트를함유하는조립물,그제조방법및프란루카스트의부착응집성개선방법
TW200835524A (en) Solid dispersion composition
JP7738697B2 (ja) 顆粒及びそれを用いた製剤
WO2019009528A2 (ko) 미라베그론의 습식과립 조성물
CN102176901B (zh) 生产可控释放口服剂型的方法
TWI850539B (zh) 顆粒及使用其之製劑
JP2004503511A (ja) 新規固体分散剤組成物
JPWO2021182469A5 (https=)
US20030212102A1 (en) Novel solid dispersion compositions
HK40082230A (en) Granules and preparation using same
JPWO2021182467A5 (https=)
JP3055799B2 (ja) パンクレアチン含有組成物
KR20260059683A (ko) 과립 및 그것을 이용한 제제
MX2013004685A (es) Composicion farmaceutica para tratar infecciones del hcv.
Zien et al. Design and characterization of diclofenac sodium microspheres prepared by ionotropic gelation technique for oral controlled drug delivery
HK40081736A (en) Granules and preparation using same
JP2006160730A (ja) 低融点薬物含有粉粒体及びその製造方法
KR20260059682A (ko) 과립 및 그것을 이용한 제제
CN105380920A (zh) 一种利塞膦酸钠缓释制剂及制备方法
TR2022010871A2 (tr) Geli̇şti̇ri̇lmi̇ş çözünme hizina sahi̇p ri̇varoksaban fi̇lm kapli tablet formülasyonlari i̇çi̇n üreti̇m yöntemi̇
Pourmand et al. Evaluation of Lipophilic Properties of Thermoplastic Granule in Formulation of Sustained Release Matrix in Solid Dosage Forms